SUMMARY
Treatment of pancreatic ductal adenocarcinoma (PDAC) has been the subject of controversy for decades. At the centre of this controversy is radiation therapy. Since PDAC is considered a systemic disease, the role of radiation therapy is debated. However, most of the available evidence is blurred by suboptimal radiation doses, less effective chemotherapy regimens and abandoned radiotherapy techniques. This article reviewed the available literature and discussed the changes in radiation therapy that have taken place over the past decade.
(BELG J MED ONCOL 2022;16(7):328–35)
